Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
Authors:
- Emilie H. ZobelEZEmilie H. Zobel
- Bernt Johan von ScholtenBSBernt Johan von Scholten
- Henrik ReinhardHRHenrik Reinhard
- Frederik PerssonFPFrederik Persson
- Tom TeerlinkTTTom Teerlink
- Tine W. HansenTHTine W. Hansen
- Hans-Henrik ParvingHPHans-Henrik Parving
- Peter K. JacobsenPJPeter K. Jacobsen
- Peter RossingPRPeter Rossing
Open Access
- 11 July 2017
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-9
Abstract
To evaluate symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) as risk markers of cardiovascular disease, all-cause mortality and deterioration in renal function in a well characterised type 2 diabetic population with microalbuminuria and without symptoms of coronary artery disease. 200 participants followed for 6.1 years. SDMA and ADMA were measured at baseline. Endpoints included (1) composite cardiovascular endpoint (n = 40); (2) all-cause mortality (n = 26); and (3) decline in eGFR of >30% (n = 42). Cox models were unadjusted and adjusted for traditional risk factors (sex, age, systolic blood pressure, LDL-cholesterol, smoking, HbA1c, creatinine and urinary albumin excretion rate). To assess if SDMA or ADMA improved risk prediction beyond traditional risk factors we calculated c statistics and relative integrated discrimination improvement (rIDI). C statistic (area under the curve) quantifies the model’s improved ability to discriminate events from non-events. rIDI quantifies the increase in separation of events and non-events on a relative scale. Higher SDMA was associated with increased risk of all three endpoints (unadjusted: p ≤ 0.001; adjusted: p ≤ 0.02). Higher ADMA was associated with all-cause mortality (unadjusted: p = 0.002; adjusted: p = 0.006), but not cardiovascular disease or decline in eGFR (p ≥ 0.29).The c statistic was not significant for any of the endpoints for either SDMA or ADMA (p ≥ 0.10). The rIDI for SDMA was 15.0% (p = 0.081) for the cardiovascular endpoint, 52.5% (p = 0.025) for all-cause mortality and 48.8% (p = 0.007) for decline in eGFR; for ADMA the rIDI was 49.1% (p = 0.017) for all-cause mortality. In persons with type 2 diabetes and microalbuminuria higher SDMA was associated with incident cardiovascular disease, all-cause mortality and deterioration in renal function. Higher ADMA was associated with all-cause mortality. SDMA and ADMA significantly improved risk prediction for all-cause mortality, and SDMA for deterioration in renal function beyond traditional risk factors.Keywords
Funding Information
- European Foundation for the Study of Diabetes (clinical research grant in Type 2 diabetes)
This publication has 33 references indexed in Scilit:
- Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective StudiesPLOS ONE, 2016
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trialDiabetologia, 2016
- Asymmetric Dimethylarginine and Cardiovascular Risk: Systematic Review and Meta‐Analysis of 22 Prospective StudiesJournal of the American Heart Association, 2015
- Relation of Asymmetric Dimethylarginine Levels to Macrovascular Disease and Inflammation Markers in Type 2 Diabetic PatientsJournal of Diabetes Research, 2014
- Genetic and Environmental Determinants of Dimethylarginines and Association With Cardiovascular Disease in Patients With Type 2 DiabetesDiabetes Care, 2014
- Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the CommunityCirculation, 2009
- Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic NephropathyDiabetes Care, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuriaDiabetic Medicine, 2007
- Elevated Plasma Asymmetric Dimethylarginine as a Marker of Cardiovascular Morbidity in Early Diabetic Nephropathy in Type 1 DiabetesDiabetes Care, 2004